Prenetics Global Limited
Prenetics Global Limited
Your view on PRE
Overview
What the company does, where it operates, and who runs it.
About Prenetics Global Limited
- Industry
- Medical - Diagnostics & Research
- Sector
- Healthcare
- CEO
- Sheng Wu Yeung
- Headquarters
- Unit 701-706, K11 Atelier King’s Road, Quarry Bay, HK
- Industry
- Medical - Diagnostics & Research
- Sector
- Healthcare
- CEO
- Sheng Wu Yeung
- Headquarters
- Unit 701-706, K11 Atelier King’s Road, Quarry Bay, HK
Prenetics Global Limited, an investment holding company, operates as a diagnostics and genetic testing company.
Its products include CircleDNA, a consumer genetic testing product; and Circle HealthPod, a rapid detection health monitoring system that allows users to take COVID-19 tests at point-of-care or at home utilizing the nucleic acid amplification test.
The company's products also comprise ColoClear, a non-invasive FIT-DNA colorectal cancer screening test; Circle SnapShot, an off-the-shelf at-home blood test; Circle Medical, a diagnostic testing product; and Circle One and F1x/Fem. Prenetics Global Limited was founded in 2014 and is headquartered in Quarry Bay, Hong Kong.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for Prenetics Global Limited, and the rating behind it. PRE last traded at $23.47; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for Prenetics Global Limited. Starting points for Prenetics Global Limited: EPS -$3.92, beta 0.25 — an Medical - Diagnostics & Research name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for Prenetics Global Limited. Prenetics Global Limited does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for Prenetics Global Limited. Trailing twelve-month EPS for Prenetics Global Limited stands at -$3.92. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for Prenetics Global Limited. Prenetics Global Limited has reported as a listed company since 2021. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Prenetics Global Limited valued side by side against its closest peers. Prenetics Global Limited is measured against Medical - Diagnostics & Research peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold Prenetics Global Limited, and how their positions are changing. At a $399.0M market value, institutional positions materially move Prenetics Global Limited's register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by Prenetics Global Limited executives and directors. Shares of Prenetics Global Limited have traded between $3.10 and $17.99 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming Prenetics Global Limited. Prenetics Global Limited is a $399.0M Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming Prenetics Global Limited. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for Prenetics Global Limited. Coverage tracks Prenetics Global Limited within Medical - Diagnostics & Research (Healthcare). Press releases and market coverage, newest first.